Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]
, 2018 Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley +17 more
core +2 more sources
Effects of RANKL-Targeted Therapy in Immunity and Cancer. [PDF]
, 2014 The role of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK system is well characterized within bone, where RANKL/RANK signaling mediates osteoclastogenesis and bone resorption.
Cheng, Michael L, Fong, Lawrence
core +2 more sources
Positioning novel biologicals in CKD-mineral and bone disorders [PDF]
, 2017 Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian +5 more
core +1 more source
Scientific Reports, 2023 Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases.
Pei-An Fu +6 more
doaj +1 more source
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial [PDF]
, 2015 OBJECTIVES: To evaluate efficacy and safety of three different regimens of denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), for Japanese patients with rheumatoid arthritis (RA). METHODS:
Genant, Harry K. +8 more
core +1 more source
Bone Reports, 2020 Discontinuation of denosumab is associated with the increase of bone turnover markers to above-baseline levels (so-called rebound in bone turnover) and rapid bone loss.
Masafumi Kashii +3 more
doaj +1 more source
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis [PDF]
Endocrinology and Metabolism, 2015 Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased ...
Yong-Ki Min
doaj +1 more source
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone [PDF]
, 2016 Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT.
Angelo Paolo Dei Tos +15 more
core +1 more source
Health Technology Assessment, 2013 Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford +10 more
doaj +1 more source
Recent Developments in Osteogenesis Imperfecta [PDF]
, 2015 Osteogenesis imperfecta (OI) is an uncommon genetic bone disease associated with brittle bones and fractures in children and adults. Although OI is most commonly associated with mutations of the genes for type I collagen, many other genes (some ...
Albert, Carolyne +3 more
core +2 more sources